When measuring disease severity and progression in patients with multiple sclerosis (MS), there are several approaches that provide different information and have varying strengths and weaknesses, according to Daniel Kantor, MD, president of Kantor Neurology.
When measuring disease severity and progression in patients with multiple sclerosis (MS), there are several approaches that provide different information and have varying strengths and weaknesses, according to Daniel Kantor, MD, president of Kantor Neurology.
Transcript
How is disease severity and progression in patients with multiple sclerosis being measured?
Sometimes MS gets compared to a snowflake. We say that everybody with MS is unique in their own way and beautiful in their own way, much like a snowflake. That can also mean, though, that it’s difficult to study large populations of people with multiple sclerosis, because different people have different symptoms.
What we’ve been able to do since the early ‘90s is really study multiple sclerosis systematically, and we’ve used as our primary end point in many of our studies something called the annualized relapse rate. We also use, sometimes as a co—primary end point and sometimes as a secondary end point, we use some form of disability measurement. Now, there’s problems with both the measurement of annualized relapse rate as well as disability.
For example, annualized relapse rate looks at a population. It says, well, there’s 100 people in this group, each person had 1 relapse, that’s 100 relapses over that year, that’s an annualized relapse rate of 1. If we have 100 people, and 50 people have 2 relapses or attacks and 50 people have 0, that’s still a total of 100 relapses over a population of 100 people over the course of a year, which is still an annualized relapse rate of 1. Two very separate populations, very, very distinct, yet they have the same annualized relapse rate.
The problem with our disability measurement is that we use a scale that unfortunately is not linear. We’re using a scale called the Expanded Disability Status Scale score, and that says that 0 means no disability and 10 means death due to multiple sclerosis. But 6 means you used 1 cane, 6.5 means bilateral support, 7 means that you’re sometimes in a wheelchair, and as you can see it drops off very fast.
We are using other measures of disability. We’ve tried to use something called the Multiple Sclerosis Functional Composite, and that looks not just at walking at 25 feet, that also looks at using your hands in something called the 9-hole peg test, also using your thinking, and we’ve changed a little bit some of the testing that we’re doing. Some people have proposed looking at low-contrast visual acuity, meaning you look at that eye chart but what you do is you just gray it out a little bit, that becomes harder for somebody with optic neuritis to see. And so those are other clinical ways that we’re trying to measure disability.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More